Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Aspirin helps increase survival from TB meningitis by reducing brain inflammation and preventing the disease from blocking blood vessels in the brain that cause parts of the brain to die, commonly called ‘stroke’.

TB bacteria
Acid-fast bacilli of Myobacterium tuberculosis (the red cords; the blue blobs are white cells) in the cerebrospinal Fluid of a patient with tuberculous meningitis

These findings were recently published in eLife, from a phase II clinical trial led by Professor Guy Thwaites

With funding from the Wellcome Trust, OUCRU researchers  investigated whether the addition of aspirin at low (81mg/day) or high (1000mg/day) dose, or placebo, to the first 60 days of current standard TB meningitis treatment (anti-TB drugs and steroids) was safe and reduced new strokes or death from this severe disease.

Professor Thwaites was recently interviewed about this work for the eLife podcast, and you can listen to the interview on eLife podcast (at 14:45 on the clock)

eLife have also published an insight article, which discusses this study and its results

Similar stories

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

What does the Oxford Malaria vaccine mean for Asia?

A trial in infants and toddlers in Burkina Faso showed that experimental malaria vaccine R21/MM confers 77% protection, an unprecedented level and the first malaria vaccine to exceed WHO’s goal of 75% efficacy. While a larger trial is needed to assess its safety and efficacy, R21/MM may substantially reduce child mortality in Sub-Saharan Africa. But this vaccine may be less relevant to Asia Pacific where malaria causes severe morbidity and mortality in all age groups, asymptomatic malaria infections are frequent, and the vaccine may not be effective against P. vivax.

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.

COVID-19 in Nepal: a lack of preparedness and a lack of vaccines

COVID-19 in Nepal is out of hand and slowly, but surely tracking the infection in India. Although many healthcare workers have been vaccinated throughout the country, the actual vaccination rate is likely very low for the entire country. Buddha Basynat discusses Nepal’s COVID response so far, and why vaccines are an urgent priority.

Buddha Basnyat joins the RSTMH Board of Trustees

Director for the Oxford University Clinical Research Unit Nepal, Professor Buddha Basnyat is a medical doctor based in Kathmandu, Nepal. His research interests are infectious diseases and high altitude medicine, and he has almost 300 publications in peer-reviewed medical journals. One of his primary interests is to encourage young people to do clinical research.